Read this company snapshot
Daily valuation snapshot
Annovis Bio, Inc.: source evidence dated 2026-10-09.
- Daily close (USD)
- $1.21
- Market capitalization (USD)
- $51,553,443.92
- Price / earnings (TTM)
- Not reported
- Price / book
- Not reported
The source values and product destination above identify the example to inspect.
What business is this, and what does its dated valuation mean?
Check the market day first. P/E uses trailing earnings; book value and market capitalization answer different questions.
Daily valuation dataset and column definitionsOpen the company research view or ask Aurora to reconcile reporting periods, earnings, debt and the figures behind the valuation.
Research ANVS in the app
Open the company research view or ask Aurora to reconcile reporting periods, earnings, debt and the figures behind the valuation.
Research ANVS in the appKeep reporting dates and units beside the answer, and inspect its original citations.
Company overview
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 2/3 to treat alzheimer's disease, as well as in phase 3 to treat parkinson's disease; and is in phase 2 clinical trial to treat lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial to treat later stages of alzheimer's disease and dementia. The company was incorporated in 2008 and is headquartered in Malvern, Pennsylvania.
Daily valuation snapshot
See the complete daily valuation snapshot
These values come from the daily market snapshot dated 2026-10-09. TTM means trailing twelve months. Use the market date when comparing ANVS with another company.
Scroll sideways to compare all columns. Select a heading to sort.
| Daily close (USD) | $1.21 |
| Market capitalization (USD) | $51,553,443.92 |
| Price / earnings (TTM) | Not reported |
| Price / book | Not reported |
No matching rows. Clear the filter to see all records.
Read ANVS's valuation metrics
Company size
Annovis Bio, Inc.'s recorded market capitalization is $51,553,443.92. It measures the market value of the company's equity, rather than its revenue or cash balance.
Price relative to earnings
P/E compares share price with trailing annual earnings per share. For a company with losses, inspect the earnings figures directly rather than treating a negative multiple as a cheap valuation.
Price relative to book equity
Price-to-book compares market equity value with recorded book equity. Intangible assets, profitability and the company's business affect how useful the comparison is.
Research Annovis Bio, Inc. with Aurora
Use the snapshot above to ask a specific question about ANVS. Ask for the report period and the figures behind the explanation, then compare the answer with the company's business description.
Continue the research
Follow ANVS's ownership disclosures to see who filed a transaction or position and when it became public. To turn a research idea into a strategy, define an entry rule and test its dated observations.